1	IN THE UNITED STATES DISTRICT COURT
2	FOR THE NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
4	
5	
6	************
7	IN RE:
8	NATIONAL PRESCRIPTION OPIATE MDL NO. 2804
	LITIGATION
9	
	This document relates to: Case No. 17-MD-2804
10	
	All cases Hon. Dan A. Polster
11	***************
12	HIGHLY CONFIDENTIAL - SUBJECT
13	TO FURTHER CONFIDENTIALITY REVIEW
14	VIDEOTAPED DEPOSITION OF:
15	RONALD LINK
16	MOTLEY RICE
17	55 Cedar Street
18	Providence, Rhode Island
19	December 11, 2018 9:09 a.m.
20	
21	
22	Darlene M. Coppola
23	Registered Merit Reporter
24	Certified Realtime Reporter
1	

```
APPEARANCES:
 1
 2
   Representing the Plaintiffs:
 3
         LEVIN PAPANTONIO THOMAS MITCHELL
 4
         RAFFERTY PROCTOR PA
         316 Baylen Street
 5
         Pensacola, FL 32502
 6
 7
        BY: WILLIAM BAKER, ESQUIRE
 8
              STEPHANIE HACKMAN, PARALEGAL
 9
        T 850.485.4160
10
11 Representing the Plaintiffs:
12
         GARSON JOHNSON, LLC
13
         101 West Prospect Avenue
14
         Midland Building
15
   Suite 1600
16
    Cleveland, OH 44115
17
        BY: JAMES A. DEROCHE, ESQUIRE
18
              PATTI CARDINAL, ESQUIRE
19
              (Via telephone)
20
        T 216.296.9330
21
         E Jderoche@weismanlaw.com
22
23
    (Continued on the next page)
24
```

```
APPEARANCES (Continued):
 1
 2
    Representing the Plaintiffs:
 3
    (Via telephone)
 4
          WEISMAN, KENNEDY & BERRIS CO., L.P.A.
 5
         101 West Prospect Avenue
 6
         Midland Building
         Suite 1600
 7
 8
         Cleveland, OH 44115
         BY: DANIEL P. GOETZ, ESQUIRE
 9
10
         T 216.781.1111
11
         E dgoetz@weismanlaw.com
12
13
    Representing the Plaintiffs:
14
    (Via telephone and video stream)
15
         MOTLEY RICE LLC
16
         28 Bridgeside Boulevard
         Mount Pleasant, SC 29464
17
18
         BY: MICHAEL E. ELSNER, ESQUIRE
19
               AMANDA UNTERREINER, ESQUIRE
20
         T 843.216.9000
21
         E melsner@motleyrice.com
22
            aunterreiner@motleyrice.com
23
24
     (Continued on next page)
```

```
APPEARANCES (Continued):
 1
    Representing the Defendant CVS Indiana, CVS RX
 2
     Services and the Witness:
 3
 4
          ZUCKERMAN SPAEDER LLP
          1800 M Street NW
 5
         Suite 1000
 6
         Washington, DC 20036
 7
 8
         BY GRAEME W. BUSH, ESQUIRE
          T 202.778.1800
 9
10
          E gbush@zuckerman.com
11
12
     Representing the Defendants Endo Health
13
     Solutions Inc., Endo Pharmaceuticals Inc.,
14
     Par Pharmaceutical, Inc.; Par Pharmaceutical
15
     Companies, Inc. (FKA Par Pharmaceutical
    Holdings, Inc.):
16
    (Via telephone and video stream)
17
18
         ARNOLD & PORTER KAYE SCHOLER, LLP
19
         777 South Figueroa Street
20
         44th Floor
21
          Los Angeles, CA 90017-5844
22
          BY: TIFFANY IKEDA, ESQUIRE
23
         T 213.243.4238
24
         E tiffany.ikeda@arnoldporter.com
```

```
APPEARANCES (Continued):
 1
    Representing the Defendant Walmart:
 2
    (Via telephone and video stream)
 3
 4
          JONES DAY
         77 West Wacker
 5
         Chicago, IL 60601
 6
 7
         BY: JOANNE CACERES, ESQUIRE
 8
         T 312.269.4159
         E jcaceres@jonesday.com
 9
10
    Representing the Defendant HBC Company:
11
12
    (Via video stream)
13
         MARCUS & SHAPIRA LLP
14
         One Oxford Centre
15
         35th Floor
16
         Pittsburgh, PA 15219
17
          BY: RICHARD HALPERN, ESQUIRE
         T 412.471.3490
18
19
         E rhalpern@marcus-shapira.com
20
21
22
    (Continued on next page)
23
24
```

```
APPEARANCES (Continued):
 1
 2
   Representing the Defendant McKesson:
    (Via video stream)
 3
         COVINGTON & BURLING LLP
 4
         1999 Avenue of the Stars
 5
         Los Angeles, CA 90067
 6
 7
         BY: MICHAEL LANOSA, ESQUIRE
 8
         T 424.332.4780
 9
         E mlanosa@cov.com
10
    Representing the Defendant Cardinal Health:
11
12
    (Via video stream)
13
         WILLIAMS & CONNOLLY LLP
14
         725 Twelfth Street, NW
15
         Washington, DC 20005
16
         BY: ANDREW MCBRIDE, ESQUIRE
17
         T 202.434.5686
         E amcbride@wc.com
18
19
20
    (Continued on next page)
21
22
23
24
```

```
1
    Appearances (Continued):
 2
     Representing the Defendant AmerisourceBergen:
 3
 4
    (Via video stream)
 5
          JACKSON KELLY PLLC
         500 Lee Street East
 6
 7
         Charleston, WV 25301
 8
         BY: GRETCHEN CALLAS, ESQUIRE
         T 304.340.1000
 9
10
         E gcallas@jacksonkelly.com
11
12
    Also Present:
13
14
    Gina Veldman, Trial Services
15
    Robert Martignetti, CLVS
16
17
18
19
20
21
22
23
24
```

1		INDEX	
2		EXAMINATION	
3	Witness Name		Page
4	RONALD LINK		1 4 9 0
5		Mr. Baker	
6	_	c. DeRoche	
7			
		EXHIBITS	
8			
	CVS-LINK	Description	Page
9			
	No. 36A	E-mail, CVS 000012286	18
10			
	No. 10A	E-mail dated January	22
11		9, 2014	
12	No. 25	Track One CVS Store	24
		Information, Bates CVS	
13		000007362 through 7364	
14	No. 3	"Poisoning Deaths:	37
		Opioid Analgesics"	
15			
	No. 60	CVS Logistics, June 6,	47
16		2014, CVS 000039935	
		and 936	
17			
	No. 113	Logistics Planning	54
18		Update, CVS 000100362	
		through 364	
19	100	- 17 922 00000000	
0.0	No. 19B	E-mail, CVS 000003076	57
20	No. 40	Tule: 1 2012 tibel	61
21	No. 49	July 1, 2013 Wholesale	61
21		Supply Agreement, CVS	
22		000030750 through 30808	
22		30000	
24			
Z4			

1		INDEX	
2		EXHIBITS	
3	CVS-LINK	Description	Page
4	No. 50	July 1, 2009 Wholesale	65
		Supply Agreement, CVS	
5		000030817 through	
		30891	
6			
	No. 51	January 1, 2004,	67
7		Wholesale Supply	
		Agreement, CVS	
8		000030892 and 30995	
9	No. 102	E-mail, CVS 000091508	73
		through 1518	
10			
	No. 58	SOP, Bates CVS 34375	83
11		through 34378	
12	No. 12	SOM Program, CVS	89
		000002188 and CVS	
13		000034375 through 378	
14	No. 89	CVS SOM, May 2014, CVS	93
		000081680 through 1681	
15			
	No. 120	E-mail, CVS 000076135	95
16			
	No. 87	SOM, January 16, 2014,	95
17		CVS 000078029 through	
1.0		8031	
18	NT - 104	D	0.0
1.0	No. 104	E-mail, CVS 0000103329	99
19	No. 10	E mail CVC	110
20	No. 18	E-mail, CVS	112
20		00007525204 through 25259	
21		4343 <i>3</i>	
<u>~</u> _	No. 48	CVS Distribution	116
22	110. 10	Center Policy, CVS	110
		000024877 through	
23		24941	
24			

1		INDEX	
2		EXHIBITS	
3	CVS-LINK	Description	Page
4	No. 57	E-mail, CVS 000034234	120
		through 234	
5		_	
	No. 94	E-mail, CVS 000087889	123
6		and 890	
7	No. 98	E-mail, CVS 000089188	123
8	No. 70	E-mail, CVS 000057751	124
		through 754	
9			
	No. 97	E-mail, CVS 000088956	129
10		with Attachment, CVS	
		000088957 through 9025	
11			
	No. 81	E-mail, CVS 000075299	132
12		with Attachment, CVS	
		000075300 through	
13		75312	
14	No. 36	E-mail, CVS 000012286	146
15	No. 67	E-mail, CVS 000055834	149
16	No. 90	E-mail, CVS 000083367	152
		with Attachment,	
17		Suspicious Order	
		Monitoring for	
18		PSE/Control Drugs	
19	No. 71	E-mail, CVS 000057759	155
		and 55834	
20			
	No. 43	E-mail, CVS	157
21		0000000022040 through	
		2053	
22			
	No. 106	E-mail, CVS 000029867	166
23		through 870	
24			
1			ı

1		INDEX	
2		EXHIBITS	
3	CVS-LINK	Description	Page
4	No. 107	E-mail, CVS 000022230	171
		and 231	
5			
	No. 34	Notes, CVS 000010529	187
6		through 532	
7	No. 103	E-mail dated May 15,	189
		2014	
8			
	No. 119	Suspicious Order	198
9		Monitoring Training,	
		CVS 000106514 through	
10		6561	
11	No. 95	E-mail, CVS 000088523,	202
		Six Pages	
12			
	No. 55	Business Idea	217
13		Description, CVS	
		000034175 through 177	
14			
	No. 82	E-mail dated October	222
15		12, 2010	
16	No. 83	E-mail, CVS 000075564	226
		and 542	
17			
	No. 92	E-mail, CVS 0000/83064	232
18		with Attachment, Five	
		Pages	
19			
	No. 53	E-mail, CVS 000033579	248
20		through 581	
21	No. 62	E-mail, CVS 000055298	255
		through 302	
22			
	No. 54	E-mail, CVS 000034168	258
23		through 171	
24			

1		INDEX	
2		EXHIBITS	
3	CVS-LINK	Description	Page
4	No. 85	E-mail, CVS 000076114	264
		through 117	
5		-	
6			
7			
	No. 108	CVS DEA Visit 8/5 to	283
8		8/8/2013, CVS	
		000008389 through 8395	
9			
	No. 68	E-mail, CVS 000057736	286
10		through 738	
11	No. 40B	E-mail, CS 000017250,	305
		Nine Pages	
12		J	
	No. 111	E-mail, CVS 000099706	308
13		through 709	
14	No. 105	SOM Risk Analysis, CVS	322
		000103343	
15			
	No. 35	Memorandum, CVS	333
16		000010542 and 543	
17	No. 221	E-mail, CVS 000103859	337
		and 3867	
18			
	No. 222	CVS 3322 - Brookpark	342
19		Rd., Cleveland, OH,	
		Orders of HCPs	
20			
	No. 223	Brookpark RD CVS	345
21		Orders Places to IN DC	
22	No. 201	Hydrocodone Shipments:	353
		CVS Pharmacy No. 3322	
23			
	No. 213	E-mail, CVS 000106598	357
24		through 601	

1	THE VIDEOGRAPHER: We are now on
2	the record. My name is Robert Martignetti.
3	I'm a videographer for Golkow Litigation
4	Services. Today's date is December 11, 2018,
5	and the time is 9:09 a.m.
6	This video deposition is being held in
7	Providence, Rhode Island In Re: National
8	Prescription Opiate Litigation. The deponent
9	is Ron Link. Counsel will be noted on the
10	stenographic record.
11	The court reporter is Darlene Coppola
12	and will now swear in the witness.
13	
14	RONALD LINK,
15	witness, having first been
16	
10	satisfactorily identified and duly sworn,
17	satisfactorily identified and duly sworn, testifies and states as follows:
17	
17	testifies and states as follows:
17 18 19	testifies and states as follows: DIRECT EXAMINATION
17 18 19 20	testifies and states as follows: DIRECT EXAMINATION BY MR. BAKER:
17 18 19 20 21	DIRECT EXAMINATION BY MR. BAKER: Q. Your name is Ronald Link?

O. Could you tell us what day of the week 1 2 it is? 3 Α. It is -- gee, Tuesday. Okay. Those were direct questions. 4 5 Those were direct answers. And that's what I'm here to do, is to ask you direct questions 6 7 and get direct answers. The reason I say that 8 is because during the deposition, oftentimes witnesses will take off in a direction of ten 9 10 or twelve sentences to answer a really direct 11 question that calls for a really direct 12 answer. 13 So, for example, I asked you what day 14 of the week it was and you gave me a day. I 15 asked you what date it was, you gave me a 16 date. 17 So as we go through this deposition and I ask you direct questions that have 18 keywords, like dates --19 20 Yeah. Α. 21 -- and days and times, that's what I'm Q. 22 looking for. 23 Fair enough? 24 Α. Yeah.

Q. So you are what with CVS? 1 2 I am no longer employed with CVS. Α. When were you employed with CVS? 3 Q. I was employed until this past 4 December 2017. 5 You were employed from when to when? 6 1994 to 2017. 7 Α. 8 During the period of 1994 through 2017, what positions did you hold and on what 9 dates did you hold those positions? 10 11 First three years, '94 to '97, I was 12 the director of operations for the Lumberton 13 DC. When you say DC, that's an acronym for 14 distribution center? 15 A. Distribution center. 16 17 Q. You understand that a jury will be hearing what your testimony is today. So when 18 19 you use acronyms, you have to speak up and 20 tell me what those acronyms are. Correct? 21 Α. Correct. 22 Q. So when we say DC throughout this deposition, you're talking about distribution 23 24 center?

Α. Distribution center. 1 2 When we say SOM, we're talking about O. suspicious order monitoring, correct? 3 4 Α. Correct. 5 Q. When we talk about SOP, we're talking about standards of procedure; is that right? 6 7 Α. Correct. 8 Standard operating procedures? 9 Α. Standard operating procedures. When we talk about P&P, we're talking 10 O. about policy and procedure, correct? 11 12 Α. Correct. 13 So when we say an SOM, P&P, all those 14 acronyms, you understand what we're talking 15 about, correct? 16 A. Correct. 17 So go ahead and tell me from 1994 until when, you were what? 18 1994 until I think it was 2007, I was 19 20 vice president of logistics. And then from 21 2007 through 2017, I was senior VP of 22 logistics. Vice president of logistics would be 23 24 what in relation to the hierarchy of logistics

at CVS? 1 2 Α. I reported into a senior vice president of logistics. So it would be --3 What senior -- I'm sorry. Go ahead. 4 5 Α. Yeah, so I -- I would probably -- I would be viewed as the number two person, I 6 7 guess. 8 Q. And then from 2007 to 2017, you were 9 the number one person with respect to 10 logistics at CVS; is that correct? 11 That's correct. There are multiple different CVS names 12 Q. 13 of corporations. 14 Which CVS did you work for from 2007 15 through 2017? 16 Α. The CVS Pharmacy. 17 CVS Pharmacy is located where? Woonsocket, Rhode Island. 18 19 O. That's where the corporate offices 20 are, correct? 21 A. Correct. 22 Q. And the distribution centers that you were in charge of as the number one person 23 24 from 2007 through 2017, that's where the CVS

```
suspicious order monitoring program was run
 1
 2
          for narcotics; is that correct?
                          MR. BUSH: Objection.
 3
          BY MR. BAKER:
 4
                   Is that right?
 5
              O.
                   Let me rephrase the question.
 6
 7
                   Did the logistics department that you
 8
          were head of from 2007 through 2017 own the
 9
          suspicious order monitoring program?
                   Not -- not that entire period of time.
10
              Α.
11
              Q. During what period of time did
12
          logistics own that program?
13
                   We got directly involved with that
              Α.
14
          around 2012, I believe the date was.
15
              Ο.
                   Let me show you what's marked as
16
          exhibit -- let me show you what's marked as
          Exhibit 36A.
17
18
                    (Exhibit No. 36A marked for
19
20
          identification.)
21
22
          BY MR. BAKER:
                   This is an e-mail from Mr. Mark
23
              Ο.
24
          Nicastro to you dated 8/18/13. And in the
```

```
last paragraph it says, "I know Tom and Craig
 1
 2
          want the process in Woonsocket, and if they're
          going to own it, staff it, and manage it,
 3
          fine. My understanding is logistics owns this
 4
 5
          process, so either Dan or I have it."
                          MR. BUSH: Dean, I think you
 6
 7
          meant.
 8
          BY MR. BAKER:
                   "Dean or I have it."
 9
              Q.
                   Did I state that correct?
10
11
              Α.
                   Correct.
12
              Q.
                   So what that means is that at least we
          know that in 2015 that logistics owned the SOM
13
14
          process; is that correct?
15
              Α.
                   That's correct.
16
                   And you say that they started owning
          it -- the logistics department started owning
17
          it when?
18
                   The transition, I believe, was roughly
19
          the year prior.
20
21
              Q.
                   In 2012?
22
              Α.
                   2012.
23
                   Which department owned the SOM process
24
          before it was transferred to logistics?
```

Α. Loss prevention. 1 2 Where is loss prevention located? Q. In Woonsocket, Rhode Island. 3 Α. Who was the head of loss prevention 4 Ο. 5 during the period of time that the SOM process was run out of Woonsocket? 6 A. Judy Hughes. 7 8 Q. Where is Judy Hughes today? I believe she's still in Woonsocket. 9 Α. When you were vice president of 10 O. 11 logistics before you became senior vice 12 president, were you in contact with Judy 13 Hughes regarding the SOM program or not? 14 Α. I don't recall. 15 Q. Sir? 16 Α. I do not recall. 17 During the period of time that you Q. were senior vice president from 2007 through 18 2017 of logistics, were you in touch with Amy 19 20 Propatier, the DEA compliance coordinator for 21 CVS? 22 Α. Not directly. 23 Did you even know that she held the Q. 24 position of DEA's compliance coordinator?

Α. Yes, I did. 1 2 Did you ever have any communication Q. with her? 3 Not directly, no. 4 5 Ο. During the period of time that the suspicious order monitoring program was owned 6 by the logistics department at CVS from 20127 8 through 2014, when you were employed there, 9 you had no communication with the DEA 10 compliance coordinator, which at that time was 11 Amy Propatier? Not directly. 12 Α. 13 What about indirectly? Ο. 14 Α. I don't recall. I don't recall. 15 So you don't recall any communication Q. 16 with the DEA compliance coordinator when you were the senior vice president of logistics at 17 CVS when the logistics department owned the 18 suspicious order monitoring program, correct? 19 20 Α. Correct. 21 Let me show you Document No. 10A. Q. 22 This is an e-mail. 23 24

```
(Exhibit No. 10A marked for
 1
 2
          identification.)
 3
          BY MR. BAKER:
 4
                   This is an e-mail from Dean Vanelli to
 5
              Ο.
          you, Ronald Link, dated 1/9/2014.
 6
 7
                   At the bottom it says, "Suspicious
 8
          order monitoring program," it says, "assumed
          ownership of suspicious order monitoring
 9
10
          program."
11
                   We know from your testimony at least
12
          that the suspicious order monitoring program
13
          was owned by logistics in 2012, correct?
14
              Α.
                   Correct.
15
              Ο.
                   So this is not accurate that the
16
          assumption of the ownership was in 2014. The
          assumption of the ownership was in 2012.
17
          Correct?
18
                          MR. BUSH: Objection.
19
20
          BY MR. BAKER:
21
              Q.
                   Does that make sense?
                   (Witness reviews document.)
22
              Α.
23
                   Is that yes or no?
              Q.
24
                   I'm just not clear on the dates right
```

now. I apologize. 1 2 Q. We'll move on. 3 But from your recollection, it was in 2012 that logistics started to own the SOM 4 5 program; is that correct? I believe that was the date where the 6 7 transition took place. 8 Q. Would anybody be higher up in 9 logistics than you during the period of time 10 that the SOM program was owned by logistics 11 from 2012 to 2014? 12 I was the senior person in logistics. 13 So the answer is nobody would have Ο. 14 been higher up than you? 15 Α. No. 16 Q. Correct? 17 Α. No. 18 As the person the highest up in Q. logistics in charge of SOM, the suspicious 19 20 order monitoring program -- I want to make it 21 clear -- you never once remember communicating 22 with the DEA compliance coordinator, which was 23 Amy Propatier, correct? 24 Α. Correct.

```
Ο.
                   And you never really knew that she was
 1
 2
          DEA compliance coordinator, did you?
                          MR. BUSH: Objection.
 3
                   I knew she was the DEA compliance
 4
 5
          coordinator.
          BY MR. BAKER:
 6
 7
                   You never really knew what she did or
              Q.
 8
          didn't do with that title, correct?
                   I did not interact with her.
 9
                   Let me direct you to Exhibit No. 25,
10
11
          please. This is a list of CVS stores in Ohio.
12
                   Are these CVS stores ones that were
          served by CVS distribution centers?
13
14
15
                    (Exhibit No. 25 marked for
          identification.)
16
17
                   I -- I believe so. I mean, I have --
18
19
          I don't -- I'm not sure. I mean, from looking
20
          at the addresses, I'm not sure. I really
21
          don't know.
22
          BY MR. BAKER:
23
                   Well, let me ask you something. Would
              Q.
24
          there be anybody, other than CVS distribution
```

centers, that would have primarily distributed 1 2 narcotics to CVS pharmacies during the period of time that you were employed at CVS? 3 Wholesalers would have been. 4 5 Q. How about with respect to hydrocodone, which were class 3 narcotics? 6 At that time, it was CVS. 7 Α. Q. CVS had distribution centers 8 9 throughout the United States that you managed, 10 correct? 11 Α. Correct. 12 There were 19 total distribution Q. 13 centers; is that correct? 14 A. Currently. 15 And during the period of time that you Ο. 16 managed those distribution centers, those distribution centers, at least some of them, 17 18 had class 3 narcotics licenses to distribute narcotics, correct? 19 20 That is correct. Α. 21 Did all of them, or did just some of Q. 22 them? They all had class 3. 23 Α. 24 And class 3 narcotics, up until 0.

```
November -- excuse me -- October 6 of 2014,
 1
 2
          included hydrocodone and hydrocodone
          combination products; is that correct?
 3
                   Correct.
 4
              Α.
                   Class 2 products included OxyContin,
 5
              Ο.
          oxycodone, and those related products; is that
 6
 7
          correct?
 8
              Α.
                   Correct.
                   So the class 2 narcotic products were
 9
10
          supplied to CVS pharmacies throughout the
          United States by outside vendors, correct?
11
12
              Α.
                   Correct.
                   And those outside vendors included
13
              Q.
14
          people like McKesson, correct?
15
              Α.
                   Correct.
16
                   And it included people like Cardinal,
17
          correct?
              Α.
18
                   Correct.
                   It included people like Mallinckrodt;
19
20
          is that correct?
21
              Α.
                   I am not aware of that.
                   You're not aware?
22
              Q.
23
              Α.
                   No.
24
                   We'll get into those documents in just
              Q.
```

a few moments. 1 Yes, yes. 2 Α. So the class 3 narcotics, which would 3 have been hydrocodone combination products, 4 5 those were purchased from whom by the distribution centers to be stored in the 6 7 distribution centers? Who were they purchased 8 from? 9 Α. The purchasing department within CVS. Where would they purchase them from? 10 Ο. 11 Α. From the manufacturers, I believe. 12 Q. So from various outside vendors, 13 correct? 14 Α. Yes. 15 And then once they were stored in CVS Q. 16 distribution centers throughout the United States, at some point there were orders made 17 by each pharmacy throughout the United States 18 to those distribution centers for those 19 20 narcotics to be distributed and supplied to 21 those -- sent to those pharmacies, correct? 22 Α. Correct. 23 And those pharmacies numbered what 24 during the period of time that you were there,

ranging from when you -- when you started 1 2 until the time that you quit? A. Could you clarify the question? 3 O. Okay. You started working -- well, 4 let's cover the period of time from 2006 until 5 2014. 6 7 A. Okay. 8 How many CVS pharmacies were there, 9 approximately, in 2006 that your company 10 distributed to and then how many did that end 11 up being in 2014? 12 I don't recall the exact number in 13 2006. 14 Q. Could you give us the range? 15 Approximately 7,000? 16 A. Yeah. I was going to say maybe 6,000 stores, I would say. 17 And then in 2014, that was up to over 18 Q. 9,700; is that correct? 19 20 I believe it's about that number, Α. 21 yeah. 22 Q. So during the period of time that you 23 were the senior vice president of logistics, 24 from 2007 until 2014, we're talking about

between 18 and 19 distribution centers at that 1 2 time, correct? We did not have 19 distribution 3 centers, but we had -- I think we had 17 4 distribution centers. 5 Well, at some point, it bumped up to 6 7 19, correct? 8 Α. Correct. 9 Kansas City was the last one that you 10 opened? Recently. 11 Α. 12 Last year, correct? Q. 13 Correct. Α. Q. 14 And during this period of time, each 15 one of those distribution centers had a 16 process through which the pharmacies throughout the United States that were CVS 17 pharmacies would order their narcotics, their 18 class 3 narcotics, the hydrocodones and 19 20 hydrocodone combination products, from CVS 21 distribution centers, correct? 22 Α. Could you ask the question again? During the period of time from 2007 to 23 Ο. 24 2014 that you were senior vice president of

```
logistics --
 1
 2
              A. Right.
                   -- in charge of the suspicious order
 3
          monitoring program --
 4
              A. Right.
 5
 6
              Q. -- at CVS --
 7
              A. Right.
 8
                          MR. BUSH: Objection. Go ahead.
                          MR. BAKER: What's the
 9
         objection?
10
11
                          MR. BUSH: I don't think that's
12
          what he said. He said he was in charge of the
13
          suspicious order monitoring program.
14
         BY MR. BAKER:
15
              Q.
                   When were you -- when were you senior
         vice president of logistics at CVS?
16
17
                          MR. BUSH: That's not what I'm
18
         saying. But...
19
         BY MR. BAKER:
20
                   When were you senior vice president of
              Q.
21
         logistics at CVS?
22
              A. At 2007 through 2017.
23
                   Okay. During the period of time that
              Q.
24
         you were senior vice president of logistics at
```

CVS, did CVS pharmacies order primarily their 1 2 hydrocodone combination products and class 3 narcotics from CVS distribution centers? 3 Primarily, I would say no. 4 5 Ο. Okay. Who primarily did those pharmacies order class 3 narcotics from? 6 The wholesalers. 7 Α. 8 So those would be called outside vendors, correct? 9 10 Α. Correct. 11 So did the outside vendors then supply more quantities of narcotics to those 12 13 pharmacies during that time frame than CVS 14 distribution centers did? 15 Α. I don't know. I don't know the 16 quantities. 17 Q. When I meant primarily, I meant primarily who was the one that a pharmacy 18 19 would pick up the phone and call in order to 20 make an order? 21 Α. The wholesalers. 22 And then secondarily, they would call the CVS distribution centers? 23 24 There was a period -- there was a Α.

```
transition period where CVS did not carry, you
 1
 2
          know...
              Q. Class 3?
 3
 4
                   Class -- class, you know...
 5
              Q. So let's go from --
                          MR. BUSH: Can I -- excuse me.
 6
 7
          Can I ask both of you to make sure that you
 8
          each let the other finish, because I think
 9
          it's -- you're both talking over each other.
10
                          MR. BAKER: No problem.
11
          BY MR. BAKER:
12
              Q.
                   And if you think I'm overstepping you
          in your answer, hold your hand up and I'll let
13
14
          you finish.
15
              Α.
                   Yeah.
16
              Q. Fair enough?
17
              Α.
                   Yeah.
                   So from 2007 to 2014 when you were
18
          senior vice president of logistics, there
19
20
          was -- during that period of time from 2007
21
          through October 6 of 2014, hydrocodone
22
          combination products were considered
23
          Schedule III narcotics, correct?
24
              Α.
                   Correct.
```

Ο. There was a change in the scheduling 1 2 October 6, 2014 where HCPs or hydrocodone combination products were scheduled upward by the FDA to Schedule II? 4 5 Α. Correct. So what I'm asking is, during the 6 period of time from 2007 to 2014, October --7 8 Α. Correct. -- when HCPs were Schedule IIIs --9 10 Α. Correct. 11 -- did CVS pharmacies order those hydrocodone combination products from outside 12 vendors other than CVS distribution centers? 13 14 They did also order from outside 15 vendors, correct. 16 And did they order as much or more 17 from outside vendors than they did from CVS distribution centers, or do you know? 18 I don't know. 19 20 In addition to ordering from outside Q. 21 vendors, did the CVS pharmacies, during that 22 time frame from 2007 through 2014 October, order from CVS distribution centers when 23 24 they -- when they needed Schedule III

narcotics? 1 2 Α. Yes. 3 And my question relates back to this Exhibit No. 25, which is the list of Track 1 4 CVS stores which are in Ohio. 5 Did the CVS distribution centers, to 6 your knowledge, during the period of 2007 7 8 through 2014, October, supply class 3 narcotics, including hydrocodone combination 9 products, to that list of CVS stores? 10 MR. BUSH: Objection. 11 12 BY MR. BAKER: 13 Ο. To your knowledge? 14 My difficulty is not knowing whether 15 or not these addresses are the CVS stores, 16 but... 17 Q. I want you to assume --18 Α. Yeah. -- for the sake of my question that --19 0. 20 I've handed you Exhibit No. 25, assume that that's the list of stores in what's called the 21 22 Track 1 CVS, which would be -- which would be inclusive of Summit County, Ohio and Cuyahoga 23 24 County, Ohio.

Α. Okay. 1 2 I want you to assume that. Q. 3 Α. Okay. 4 I want you to assume -- I'm asking 5 you, for the period of 2007 through 2014, October, did CVS distribution centers supply 6 hydrocodone combination products to that list 7 8 of stores, if that is a list of Track 1 9 stores? 10 Α. If this is the accurate list, the 11 answer would be yes. 12 Q. Okay. Thank you. 13 Now, during the period of time that 14 you were employed by CVS, the CVS pharmacies 15 sold both Schedule II narcotics and Schedule 16 III narcotics, is that correct? 17 Α. Correct. Then from the period of October 2014 18 19 when the Schedule III narcotics of HCPs, 20 hydrocodone combination products, were then 21 rescheduled to Schedule IIs, at that point, 22 all of the narcotics that were sold by CVS 23 pharmacies in Schedule IIs were provided by or 24 supplied by outside vendors, correct?

Α. Correct. 1 Now, narcotics are controlled 2 O. 3 substances under federal law. You know that, 4 right? 5 Α. Yes. And you know that controlled 6 7 substances, in order to distribute those, you 8 have to have a certain type of license from the DEA, correct? 9 10 Α. Correct. Q. And you understand, as senior vice 11 12 president of logistics or prior senior vice 13 president of logistics, that that requires the 14 distribution centers to follow the rules 15 related to what DEA lays down for distribution 16 centers, correct? 17 A. Correct. Now, you're aware that during the 18 period of time of 2006, at the very least 19 20 2006, there was a period thereafter where 21 there was a build-up of the opioid crisis, 22 correct? 23 I -- I'm not -- I'm not sure about 24 what's defined as a build-up. I mean...

```
O.
                   Are you familiar that this country is
 1
 2
          in the midst of an opioid crisis?
 3
                  Yes, I am.
              Α.
 4
                   Are you familiar that that's been
          going on for at least the past ten years?
 5
 6
              Α.
                   Yes.
                   Are you familiar with the statistics
 7
              Q.
 8
          related to that?
 9
              Α.
                   I am not.
10
                          MR. BAKER: Could you please
11
          pull up the charts, the DEA charts, please, in
12
          sequence.
13
                   I'm on Plaintiffs' Exhibit 3.
14
15
                    (Exhibit No. 3 marked for
          identification.)
16
17
          BY MR. BAKER:
18
                   I'm going to show you -- well, first
19
20
          of all, you know who the DEA is -- the US DEA
21
          is, correct?
22
              Α.
                   Correct.
                   That's the United States Drug
23
              Q.
24
          Enforcement Administration, which governs the
```

regulation of narcotics, correct? 1 2 Α. Correct. Now, are you familiar with the 3 poisoning deaths of opioid analgesics having 4 increased virtually every single year from 5 1999 through 2013? 6 7 Α. I am not. 8 Are you familiar with the fact that, for instance, in 2007, when you became senior 9 vice president of logistics, that there were 10 11 14,440 -- 14,459 deaths from opioid 12 analgesics? 13 MR. BUSH: Objection. 14 BY MR. BAKER: 15 Q. Did you know that? 16 Α. I did not. Is that what that chart indicates to 17 18 you? 19 Α. It does, yeah. 20 Assuming this chart to be correct, did Q. 21 you know that, during the period of time that 22 you were senior vice president of logistics at 23 CVS, that the opioid deaths increased to a 24 peak of over 16,000 per year between 2010 and

1 2013? 2 I was not aware of that. 3 Are you aware of how many people are dying today? 4 I do not know the stat. 5 Is this something that you studied 6 O. 7 about when you were senior vice president of 8 logistics at CVS in charge of the suspicious order monitoring program? 9 I did not study it, no. 10 Α. 11 Did you ever try to familiarize 12 yourself with the extent of the crisis and the 13 extent of the deaths that were occurring in 14 the United States as a result of opioids? 15 Α. I did not. 16 Did you realize that these opioids that were causing these deaths were 17 distributed through CVS pharmacies? 18 MR. BUSH: Objection. 19 20 BY MR. BAKER: 21 Q. Or distributed to CVS pharmacies? 22 MR. BUSH: Objection. BY MR. BAKER: 23 24 Did you know that? Ο.

```
1
                          MR. BUSH: Objection.
 2
          BY MR. BAKER:
 3
              Q.
                   Yes?
 4
              Α.
                   Yes.
 5
              Ο.
                   Okay. Did you know that -- go to the
          next one -- that the International Narcotics
 6
          Control Board gathered statistics in 2012 as
 7
 8
          to who was consuming the highest amount of
          hydrocodone in the world? Did you know that?
 9
10
                   I did not.
              Α.
11
                   Did you know that the United States,
12
          according to the statistics kept by the DEA
13
          and this chart, was the country with the
14
          highest -- with the highest consumption of
15
          hydrocodone, which is -- which is 99 percent
16
          of global consumption?
                   I'm not aware of that.
17
              Α.
                   Okay. Did you know that CVS sold or
18
19
          that your distribution centers that you were
20
          in charge of during the period of 2007 through
21
          2014 distributed hydrocodone combination
22
          products to CVS pharmacies that account for
23
          part of that 99 percent?
24
              Α.
                   Yes.
```

O. Let me ask you to look at the next 1 2 chart. It's entitled "United States Rates of Opioid Overdose Deaths, Sales, and Treatment 3 Admissions of 1999 to 2010." 4 5 Do you see that chart in front of you? 6 I do. 7 Α. 8 Do you see that there are three lines. 9 One is green on the top. One is red in the 10 middle. One is blue on the bottom. 11 Do you see that chart? I do. 12 Α. 13 Have you ever seen this chart before? O. 14 Α. I have not. 15 I want you to assume that these are 16 statistics that were gathered by the United States DEA and charted as such. 17 Do you see that the top number there, 18 the top line is called "Opioid sales"? 19 20 Do you see that? 21 Α. I do. 22 Q. And do you understand that the middle line is opioid deaths, the red line? 23 24 Α. I do.

Do you see that those lines run 1 2 parallel to each other? Α. I do. 3 Do they correlate with each other, to 4 the best of your knowledge, from looking at 5 that chart? 6 Visually, they correlate. 7 Α. 8 Q. Is there, according to this visual 9 correlation, an opioid sales and opioid deaths correlation such that the higher the degree of 10 11 sales of opioids during this period of time, the higher degree of deaths during this period 12 13 of time? 14 That's a yes or no. 15 I'd say yes. Α. 16 Let's go to the next document. The next document discusses the 2012 17 Ohio drug overdose deaths. 18 19 Do you see that? 20 A. Yes. 21 Can I switch with you for just a Q. 22 second. Let me see that one that's yellowed 23 in. 24 Do you see on the top here, it says

that "Drug overdose deaths continue to be a 1 2 public health crisis in Ohio, with a 366 percent increase in the number of deaths from 3 2000 to 2012"? 4 5 Α. Yes. Okay. Were you aware of that when you 6 7 were working at CVS? Were you aware of this statistic? 8 9 Α. I was not. 10 Q. Were you aware of any of the 11 statistics that I showed you in the other 12 charts --13 Α. No. 14 Q. -- from the DEA? 15 Α. I was not. 16 Skip down four bullet points. Bullet Point No. 4 and 5. 17 Do you see her where it says "Opioids 18 19 prescription or heroin remain the driving 20 factor behind the unintentional drug overdose epidemic in Ohio, that approximately 21 22 two-thirds, or 1,272, of the drug overdoses involved any opioid in 2012, similar to 2011." 23 24 Did you know that?

Α. I did not. 1 2 Do you know that these statistics were O. 3 gathered by the Ohio Department of Health, Office of Vital Statistics analysis conducted 4 5 by the Injury Prevention Program? Did you know that? 6 I did not. 7 Α. 8 Did anybody ever show you these 9 statistics, or did you ever try to study these 10 statistics when you were employed by CVS in 11 charge of the suspicious order monitoring 12 program? 13 Α. No. 14 Did the opioid crisis and the Q. 15 statistics associated with the opioid crisis 16 have any concern of you while you were employed by CVS as the senior vice president 17 in charge of logistics? 18 19 Did that concern you at all? 20 It -- I'd say yes. Yeah. Α. 21 If it concerned you, then, why did you Q. 22 not attempt to do any research on it to see 23 the extent of the problem? 24 I had -- I had people directly

responsible for managing all that detail. 1 2 MR. BUSH: Go ahead. You can answer. It looked like Bill was going to 3 interrupt you. I just wanted to make sure you 4 5 got to answer the question. 6 BY MR. BAKER: 7 Q. But you were never told by those 8 people what the research showed; is that what 9 you're saying? 10 That's correct. A. 11 Q. Pull out the next chart, please. This 12 is called the drug diversion map. 13 MR. BUSH: I think you took the 14 exhibit from him. 15 MR. BAKER: I'm sorry. Let's 16 see that one back, please. BY MR. BAKER: 17 This is called a "Drug Diversion Map, 18 Migration Out of Florida." 19 20 Have you ever seen this map before? 21 Α. I have not. 22 Q. This map -- your lawyer can explain, 23 because we've gone over this in 24 Miss Propatier's deposition -- this map is

something that is a CVS document. 1 Did you know that? 2 I did not. A. 3 Did you know that this map was 4 contained within CVS files, the drug diversion 5 migration out of Florida map? 6 I did not. 7 Α. 8 Have you ever heard of the opioid or 9 OxyContin Express? 10 Α. I have not. 11 Q. Have you ever heard of something called the Opioid Express? 12 13 Α. No. 14 Q. Are you familiar with the concept of 15 migration of opioids out of Florida up through states north of there, inclusive of Ohio? Are 16 you familiar with that? 17 18 Α. I am not. Nobody ever attempted to explain that 19 Ο. 20 this exists? 21 Α. I'm not familiar with it. 22 MR. BAKER: Let me see that 23 back, if I could. Actually, you can have it. 24 Give me Exhibit 60, please.

```
1
                    (Exhibit No. 60 marked for
 2
         identification.)
 3
 4
         BY MR. BAKER:
 5
                   I'm handing you Exhibit 60. This is a
 6
          list of CVS logistics distribution centers in
 7
 8
         existence as of June of 2014; is that correct?
 9
              A. Correct.
10
              Q. And it lists 19 distribution centers,
11
        correct?
12
              A. Correct.
13
                  Now, you -- did you resign from CVS?
              O.
14
              Α.
                  I retired from CVS.
15
              Q. You retired?
             A. Yeah.
16
              Q. What month did you retire?
17
             Α.
                  December.
18
             Q. Of 2014?
19
20
             A. '17.
21
              Q. '17. I'm sorry.
22
                   So this is a complete list of all the
         distribution centers in the United States even
23
24
         as of now; is that correct? With the
```

exception of Kansas City. 1 2 Α. Correct. 3 Q. Is that right? 4 Α. Correct. 5 0. Kansas City is not on this list, and Kansas City would make it number 20; is that 6 right? 7 8 Α. Correct. 9 So right now, to your knowledge, there 10 are 20 distribution centers of CVS throughout the United States? 11 12 Α. Yes. 13 Is that correct? O. 14 Α. There is no DC in Puerto Rico. 15 So there are 19 distribution centers, 0. but Puerto Rico is what? 16 Puerto Rico, we had stores, but we did 17 Α. not have a distribution center there. 18 Did the suspicious order monitoring 19 Ο. 20 system that was run through your department from 2007 through 2014, when you were employed 21 22 there, did it include transactions to stores in Puerto Rico or not? 23 MR. BUSH: Objection. 24

misstates the record. 1 2 I'm not aware of that. Α. 3 BY MR. BAKER: Were there CVS retail stores in Puerto 4 5 Rico? I don't recall when we opened up 6 stores in Puerto Rico. 7 8 Q. Were there pharmacies in Puerto Rico? 9 Α. Yes. When do you believe, to the best of 10 Ο. your recollection, there were pharmacies in 11 Puerto Rico? 12 13 I don't recall. I don't recall. Α. 14 When there were pharmacies in Puerto 15 Rico during your time at CVS, did CVS supply 16 from its distribution centers any narcotics to Puerto Rico pharmacies? 17 18 Α. No. 19 When you were employed at CVS, did the 20 Puerto Rico retailers, the Puerto Rico 21 pharmacies order all of their narcotics, 22 class 2s and class 3s, from outside vendors? 23 Α. Yes. 24 During the period of time that you 0.


were employed at CVS, did any of those drugs 1 2 that were supplied to the Puerto Rico 3 pharmacies run through the suspicious order monitoring system at CVS? 4 I am -- I don't know. 5 Α. You don't recall having seen any of 6 Ο. 7 that, do you? 8 Α. I don't. 9 So Puerto Rico was an outlier on its 10 own relative to whether anybody was or wasn't 11 going to monitor that in the context of CVS's efforts; is that correct? 12 Yeah, I'm not aware, yeah. 13 Α. 14 Insofar as the suspicious order Q. 15 monitoring system that your department owned 16 from 2012 through 2014 when you were there, it 17 was responsible for doing the suspicious order monitoring of all narcotics that were received 18 19 by the pharmacies in the CVS chain throughout 20 the United States; is that correct? 21 MR. BUSH: Objection. 22 A. I'm not 100 percent sure, yeah. BY MR. BAKER: 23 24 Ο. Now, you were the person most senior

```
in the logistics department that was in charge
 1
 2
          of the suspicious order monitoring system from
          2012 through 2014, correct?
 3
 4
                   Correct.
 5
              Ο.
                   My question is was that department in
          charge of monitoring suspicious orders by all
 6
 7
          of the CVS pharmacies throughout the United
 8
          States?
 9
                   I'm not sure. Again, your -- I don't
          know. I'm not clear.
10
11
                   It was a nationwide suspicious order
12
          monitoring system, correct?
13
              Α.
                   Correct.
14
                   It wasn't something that was
15
          distribution center to distribution center in
16
          2012, was it?
                   It was all in Indiana at that point,
17
          was it not?
18
19
              Α.
                   Correct.
20
                   Okay. So it centralized in the
              Q.
21
          Indiana distribution center, correct?
22
              Α.
                   Correct.
23
                   And that's -- that's a logistics
              Q.
24
          department?
```

Α. Correct. 1 2 Where you were in charge of, Q. 3 correct? 4 Α. Correct. 5 Q. So my question is did that 6 distribution center run the suspicious order 7 monitoring system for the entire United 8 States? 9 Α. At that time yes, yes. 10 O. And so any narcotics that were ordered 11 by any CVS pharmacy, that's what you were in charge of monitoring in Indiana, correct? 12 13 MR. BUSH: Objection. 14 BY MR. BAKER: 15 Q. Is that right? 16 Α. The -- yeah, I --17 MR. BUSH: You can answer the question. 18 I am not sure, because of the 19 20 outside -- outside vendor component. 21 BY MR. BAKER: 22 Q. So let me ask it this way: With respect to class 3 narcotics, which would have 23 24 included hydrocodone combination products up

until October 2014 --1 2 Α. Correct. -- all of the suspicious order 3 monitoring that was done for the class 3 4 narcotics was run out of one distribution 5 center, which was Indiana from 2012 to 2014; 6 is that correct? 7 8 Α. That is correct. And that would include all of the 9 class 3 narcotics that would have been ordered 10 11 through CVS distribution centers, correct? 12 Α. Correct. That would have also included all of 13 14 the class 3 narcotics that were ordered 15 through outside vendors by CVS pharmacies, 16 correct? 17 Α. I'm not sure. I'm not clear on that. We'll get into that in a minute. 18 Ο. All right. 19 Α. 20 So are you familiar with even what the Q. suspicious order monitoring system monitored, 21 22 whether it be just those class 3 narcotics that were ordered from CVS distribution 23 centers or if it also included the CVS outside 24


```
vendors or not?
 1
 2
                   Do you know or have any idea?
              A. I'm not clear -- not sure.
 3
              Q. But, again, you were the senior person
 4
          in charge of that program, right?
 5
 6
                   I was the senior person responsible
          for the entire logistics organization.
 7
 8
              Q. Okay.
              A. And let me clarify. That was not my
 9
          sole responsibility, also. But I...
10
11
                          MR. BAKER: Could you hand me
12
          Exhibit 113, please.
13
14
                    (Exhibit No. 113 marked for
15
          identification.)
16
17
                          MR. BAKER: Off the record for a
18
         quick break.
                          THE VIDEOGRAPHER: The time is
19
20
         9:48 a.m., and we're off the record.
21
22
                         (Brief recess.)
23
24
                          THE VIDEOGRAPHER: The time is
```




Ο. It states, "SOM process will include 1 2 store controlled substances, orders placed with CVS warehouses and outside vendors, 3 Cardinal and McKesson, " correct? 4 5 Α. Correct. Q. So we know from looking at this, 6 7 July 8, 2013, that prospectively at least, the 8 plan was at that time to include outside 9 vendors, correct? 10 Α. Correct. Q. And up until that time, outside vendor 11 12 purchases by CVS pharmacies were not being monitored by CVS; is that correct? 13 14 Again, I was not -- I'm not aware --15 I'm not aware that it wasn't. 16 At least according to the document, that's what it indicates; is that right? 17 Α. 18 Correct. 19 O. And these are the same stores that were purchasing narcotics that were for sale 20 21 retail to the United States public; is that 22 correct? 23 Α. Correct. 24 And those included class 3 narcotics; 0.


1	is that right?
2	A. Correct.
3	Q. And those also included class 2
4	narcotics, correct?
5	A. Correct.
6	Q. So who, if anybody, was monitoring
7	those purchases by CVS pharmacies and sales to
8	the general public, to your knowledge, if
9	anybody?
10	A. I'm not aware of who would be
11	monitoring that.








Ο. Well, if the purpose of the system is 1 2 to prevent diversion and there's no system in place to do it --3 Yeah. 4 Α. 5 Q. -- then naturally, the chances of diversion increase, correct? 6 7 Α. Yes. Yeah. 8 So, see, that's one of those questions 9 that has a logical answer. So I appreciate you answering it logically rather than trying 10 to do the dance. Okay? 11 12 MR. BUSH: Objection to the 13 speech by counsel. 14 BY MR. BAKER: 15 So these narcotics that have a higher 16 opportunity for diversion when they are not being monitored, those are the same narcotics, 17 according to the DEA, that are causing deaths 18 in this opioid crisis, correct? 19 20 Correct. Α. 21 And those are the same narcotics that Ο. 22 are sold by CVS pharmacies, correct? 23 A. Correct. 24 And those are the same narcotics that Ο.















```
correct? At the bottom?
 1
 2
              A. Correct. Correct.
              Q. And this is dated July 1, 2009,
 3
 4
          correct?
 5
              A. Correct.
 6
              Q. All right. And you see on page 30840
 7
          in that agreement, but I'll show it to you
 8
         right here -- do you see on page 30817 in that
         agreement that it is signed by CVS Pharmacy,
 9
          Inc., 7/1/2009?
10
11
                  Do you see that?
12
                  I do.
              Α.
13
                   This is signed by CVS Pharmacy
              Q.
14
         Purchasing and Pharmaceutical Relations,
15
         correct?
16
              A. Correct.
                   Is that who does the purchasing of
17
18
          these outside vendor supply --
19
              A. Yes.
20
              Q. -- of narcotics to CVS pharmacies?
21
              Α.
                  Yes.
22
              Q.
                  And you're not made aware of that when
          these purchases are going on, correct?
23
24
              Α.
                  Correct.
```


1	Q. And so you really have no idea during
2	the period of time that you were in charge of
3	the suspicious order monitoring program and
4	logistics just the extent to which these
5	outside vendors were providing narcotics to
6	CVS pharmacies; is that correct?
7	A. That is correct.



























































































Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 100 of 366 PageID #: 313423 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 101 of 366 PageID #: 313424 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 102 of 366 PageID #: 313425 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 103.of 366 PageID #: 313426 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 104 of 366 PageID #: 313427 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 105 of 366 PageID #: 313428 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 106.of 366 PageID #: 313429 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 107 of 366 PageID #: 313430 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 108 of 366 PageID #: 313431 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 109 of 366 PageID #: 313432 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 110.of 366 PageID #: 313433 Highly Confidential #: 2173-39 Filed: 08/12/19 110.of 366 PageID #: 313433 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 111 of 366 PageID #: 313434 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 112 of 366 PageID #: 313435 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 113.of 366 PageID #: 313436 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 114 of 366 PageID #: 313437 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 115 of 366 PageID #: 313438 Highly Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 116.of 366 PageID #: 313439 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 117 of 366 PageID #: 313440 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 118 of 366 PageID #: 313441 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 119 of 366 PageID #: 313442 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 120 of 366 PageID #: 313443 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 121 of 366 PageID #: 313444 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 122 of 366 PageID #: 313445 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 123.of 366 PageID #: 313446 Highly Confidential #: 2173-39 Filed: 08/12/19 123.of 366 PageID #: 313446 ew




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 124 of 366 PageID #: 313447 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 125 of 366 PageID #: 313448 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 126.of 366 PageID #: 313449 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 127 of 366 PageID #: 313450 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 128 of 366 PageID #: 313451 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 129 of 366 PageID #: 313452 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 130 of 366 PageID #: 313453 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 131.of 366 PageID #: 313454 Highly Confidential #: 2173-39 Filed: 08/12/19 131.of 366 PageID #: 313454 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 132 of 366 PageID #: 313455 Highly Confidential #: 2173-39 Filed: 08/12/19 132 of 366 PageID #: 313455 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 133.of 366 PageID #: 313456 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 134 of 366 PageID #: 313457 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 135 of 366 PageID #: 313458 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 136.of 366 PageID #: 313459 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 137 of 366 PageID #: 313460 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 138 of 366 PageID #: 313461 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 139 of 366 PageID #: 313462 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 140 of 366 PageID #: 313463 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 141 of 366 PageID #: 313464 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 142 of 366 PageID #: 313465 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 143 of 366 PageID #: 313466 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 144 of 366 PageID #: 313467 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 145 of 366 PageID #: 313468 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 146.of 366 PageID #: 313469 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 147 of 366 PageID #: 313470 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 148 of 366 PageID #: 313471 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 149 of 366 PageID #: 313472 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 150 of 366 PageID #: 313473 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 151 of 366 PageID #: 313474 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 152 of 366 PageID #: 313475 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 153 of 366 PageID #: 313476 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 154 of 366 PageID #: 313477 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 155 of 366 PageID #: 313478 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 156 of 366 PageID #: 313479 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 157 of 366 PageID #: 313480 Highly Confidential #: 2173-39 Filed: 08/12/19 157 of 366 PageID #: 313480 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 158 of 366 PageID #: 313481 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 159 of 366 PageID #: 313482 Highly Confidential #: 2173-39 Filed: 08/12/19 159 of 366 PageID #: 313482




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 160 of 366 PageID #: 313483 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 161 of 366 PageID #: 313484 Highly Confidential #: 2173-39 Filed: 08/12/19 161 of 366 PageID #: 313484 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 162 of 366 PageID #: 313485 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 163 of 366 PageID #: 313486 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 164 of 366 PageID #: 313487 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 165 of 366 PageID #: 313488 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 166.of 366 PageID #: 313489 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 167 of 366 PageID #: 313490 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 168 of 366 PageID #: 313491 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 169 of 366 PageID #: 313492 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 170 of 366 PageID #: 313493 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 171 of 366 PageID #: 313494 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 172 of 366 PageID #: 313495 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 173 of 366 PageID #: 313496 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 174 of 366 PageID #: 313497 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 175 of 366 PageID #: 313498 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 176.of 366 PageID #: 313499 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 177 of 366 PageID #: 313500 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 178 of 366 PageID #: 313501 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 179 of 366 PageID #: 313502 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 180 of 366 PageID #: 313503 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 181 of 366 PageID #: 313504 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 182 of 366 PageID #: 313505 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 183 of 366 PageID #: 313506 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 184 of 366 PageID #: 313507 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 185 of 366 PageID #: 313508 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 186.of 366 PageID #: 313509 Highly Confidential Expression Further Confidential Expression







Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 188 of 366 PageID #: 313511 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 189 of 366 PageID #: 313512 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 190 of 366 PageID #: 313513 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 191 of 366 PageID #: 313514 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 192 of 366 PageID #: 313515 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 193 of 366 PageID #: 313516 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 194 of 366 PageID #: 313517 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 195 of 366 PageID #: 313518 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 196 of 366 PageID #: 313519 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 197 of 366 PageID #: 313520 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 198 of 366 PageID #: 313521 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 199 of 366 PageID #: 313522 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 200 of 366 PageID #: 313523 Highly Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 201 of 366 PageID #: 313524 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 202 of 366 PageID #: 313525 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 203 of 366 PageID #: 313526 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 204 of 366 PageID #: 313527 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 205 of 366 PageID #: 313528 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 206.of 366 PageID #: 313529 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 207 of 366 PageID #: 313530 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 208 of 366 PageID #: 313531 Highly Confidential Expression Further Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 209 of 366 PageID #: 313532 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 210 of 366 PageID #: 313533 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 211 of 366 PageID #: 313534 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 212 of 366 PageID #: 313535 Highly Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 213 of 366 PageID #: 313536 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 214 of 366 PageID #: 313537 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 215 of 366 PageID #: 313538 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 216.of 366 PageID #: 313539 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 217 of 366 PageID #: 313540 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 218 of 366 PageID #: 313541 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 219 of 366 PageID #: 313542 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 220 of 366 PageID #: 313543 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 221 of 366 PageID #: 313544 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 222 of 366 PageID #: 313545 Highly Confidential #: 2173-39 Filed: 08/12/19 222 of 366 PageID #: 313545 ew




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 223 of 366 PageID #: 313546 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 224 of 366 PageID #: 313547 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 225 of 366 PageID #: 313548 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 226.of 366 PageID #: 313549 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 227 of 366 PageID #: 313550 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 228 of 366 PageID #: 313551 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 229 of 366 PageID #: 313552 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 230 of 366 PageID #: 313553 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 231 of 366 PageID #: 313554 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 232 of 366 PageID #: 313555 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 233.of 366 PageID #: 313556 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 234 of 366 PageID #: 313557 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 235 of 366 PageID #: 313558 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 236.of 366 PageID #: 313559 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 237 of 366 PageID #: 313560 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 238 of 366 PageID #: 313561 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 239 of 366 PageID #: 313562 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 240 of 366 PageID #: 313563 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 241 of 366 PageID #: 313564 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 242 of 366 PageID #: 313565 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 243 of 366 PageID #: 313566 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 244 of 366 PageID #: 313567 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 245 of 366 PageID #: 313568 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 246.of 366 PageID #: 313569 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 247 of 366 PageID #: 313570 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 248 of 366 PageID #: 313571 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 249 of 366 PageID #: 313572 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 250 of 366 PageID #: 313573 Highly Confidential Expression Further Confidential



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 251 of 366 PageID #: 313574 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 252 of 366 PageID #: 313575 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 253 of 366 PageID #: 313576 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 254 of 366 PageID #: 313577 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 255 of 366 PageID #: 313578 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 256 of 366 PageID #: 313579 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 257 of 366 PageID #: 313580 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 258 of 366 PageID #: 313581 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 259 of 366 PageID #: 313582 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 260 of 366 PageID #: 313583 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 261 of 366 PageID #: 313584 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 262 of 366 PageID #: 313585 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 263 of 366 PageID #: 313586 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 264 of 366 PageID #: 313587 Highly Confidential Exercise




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 265 of 366 PageID #: 313588 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 266.of 366 PageID #: 313589 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 267 of 366 PageID #: 313590 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 268 of 366 PageID #: 313591 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 269 of 366 PageID #: 313592 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 270 of 366 PageID #: 313593 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 271 of 366 PageID #: 313594 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 272 of 366 PageID #: 313595 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 273 of 366 PageID #: 313596 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 274 of 366 PageID #: 313597 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 275 of 366 PageID #: 313598 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 276 of 366 PageID #: 313599 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 277 of 366 PageID #: 313600 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 278 of 366 PageID #: 313601 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 279 of 366 PageID #: 313602 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 280 of 366 PageID #: 313603 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 281 of 366 PageID #: 313604 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 282 of 366 PageID #: 313605 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 283 of 366 PageID #: 313606 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 284 of 366 PageID #: 313607 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 285 of 366 PageID #: 313608 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 286.of 366 PageID #: 313609 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 287 of 366 PageID #: 313610 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 288 of 366 PageID #: 313611 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 289 of 366 PageID #: 313612 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 290 of 366 PageID #: 313613 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 291 of 366 PageID #: 313614 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 292 of 366 PageID #: 313615 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 293 of 366 PageID #: 313616 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 294 of 366 PageID #: 313617 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 295 of 366 PageID #: 313618 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 296 of 366 PageID #: 313619 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 297 of 366 PageID #: 313620 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 298 of 366 PageID #: 313621 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 299 of 366 PageID #: 313622 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 300 of 366 PageID #: 313623 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 301 of 366 PageID #: 313624 Highly Confidential #: 2173-39 Filed: 08/12/19 301 of 366 PageID #: 313624 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 302 of 366 PageID #: 313625 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 303 of 366 PageID #: 313626 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 304 of 366 PageID #: 313627 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 305 of 366 PageID #: 313628 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 306.of 366 PageID #: 313629 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 307 of 366 PageID #: 313630 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 308 of 366 PageID #: 313631 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 309 of 366 PageID #: 313632 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 310 of 366 PageID #: 313633 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 311 of 366 PageID #: 313634 Highly Confidential



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 312 of 366 PageID #: 313635 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 313.of 366 PageID #: 313636 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 314 of 366 PageID #: 313637 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 315.of 366 PageID #: 313638 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 316.of 366 PageID #: 313639 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 317 of 366 PageID #: 313640 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 318 of 366 PageID #: 313641 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 319 of 366 PageID #: 313642 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 320 of 366 PageID #: 313643 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 321 of 366 PageID #: 313644 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 322 of 366 PageID #: 313645 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 323.of 366 PageID #: 313646 Highly Confidential #: 2173-39 Filed: 08/12/19 323.of 366 PageID #: 313646 ew




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 324 of 366 PageID #: 313647 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 325 of 366 PageID #: 313648 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 326 of 366 PageID #: 313649 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 327 of 366 PageID #: 313650 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 328 of 366 PageID #: 313651 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 329 of 366 PageID #: 313652 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 330 of 366 PageID #: 313653 Highly Confidential




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 331 of 366 PageID #: 313654 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 332 of 366 PageID #: 313655 Highly Confidential #: 2173-39 Filed: 08/12/19 332 of 366 PageID #: 313655 Review







Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 334 of 366 PageID #: 313657 Highly Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 335 of 366 PageID #: 313658 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 336.of 366 PageID #: 313659 Highly Confidential Ey Review







Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 338 of 366 PageID #: 313661 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 339 of 366 PageID #: 313662 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 340 of 366 PageID #: 313663 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 341 of 366 PageID #: 313664 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 342 of 366 PageID #: 313665 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 343.of 366 PageID #: 313666 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 344 of 366 PageID #: 313667 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 345 of 366 PageID #: 313668 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 346 of 366 PageID #: 313669 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 347 of 366 PageID #: 313670 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 348 of 366 PageID #: 313671 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 349 of 366 PageID #: 313672 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 350 of 366 PageID #: 313673 Highly Confidential



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 351 of 366 PageID #: 313674 Highly Confidential #: 2173-39 Filed: 08/12/19 351 of 366 PageID #: 313674 Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 352 of 366 PageID #: 313675 Highly Confidential Expression Further Confidential Expression




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 353 of 366 PageID #: 313676 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 354 of 366 PageID #: 313677 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 355 of 366 PageID #: 313678 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 356 of 366 PageID #: 313679 Highly Confidential Expression Further Confidential Expression Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 357 of 366 PageID #: 313680 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 358 of 366 PageID #: 313681 Highly Confidential Ey Review




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 359 of 366 PageID #: 313682 Highly Confidential #: 2173-39 Filed: 08/12/19 359 of 366 PageID #: 313682




Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 360 of 366 PageID #: 313683 Highly Confidential Expression Further Confidential Expression



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 361 of 366 PageID #: 313684 Highly Confidential Ey Review



Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 362 of 366 PageID #: 313685 Highly Confidential Expression Further Confidential Expression



5	MR. DEROCHE: I have nothing
6	further.
7	MR. BAKER: That's it.
8	MR. BUSH: People on the phone
9	don't have anything? I guess, give me one
10	second.
11	Off the record.
12	THE VIDEOGRAPHER: The time is
13	3:26 p.m., and we're off the record.
14	
15	(Off the record at 3:26 p.m.)
16	
17	THE VIDEOGRAPHER: The time is
18	3:27 p.m.
19	This deposition has concluded, and we
20	are off the record.
21	
22	(Deposition concluded at 3:27 p.m.)
23	
24	

1	CERTIFICATION		
2	I, DARLENE M. COPPOLA, a Notary Public, do hereby		
3	certify that RONALD LINK, after having satisfactorily		
4	identifying himself, came before me on the 11th day of		
5	December, 2018 in Providence, Rhode Island, and was by me		
6	duly sworn to testify to the truth and nothing but the		
7	truth as to his knowledge touching and concerning the		
8	matters in controversy in this cause; that he was		
9	thereupon examined upon her oath and said examination		
10	reduced to writing by me; and that the statement is a true		
11	record of the testimony given by the witness, to the best		
12	of my knowledge and ability.		
13	I further certify that I am not a relative or		
14	employee of counsel/attorney for any of the parties, nor a		
15	relative or employee of such parties, nor am I financially		
16	interested in the outcome of the action.		
17	WITNESS MY HAND THIS 14th day of December, 2018.		
18			
19			
20			
21	DARLENE M. COPPOLA My commission expires:		
22	NOTARY PUBLIC November 11, 2022		
23	REGISTERED MERIT REPORTER		
24	CERTIFIED REALTIME REPORTER		

1	IN THE UNITED STATES DISTRICT COURT			
2	FOR THE NORTHERN DISTRICT OF OHIO			
3	EASTERN DIVISION			
4				
5				
6	***********			
7	IN RE:			
8	NATIONAL PRESCRIPTION OPIATE			
	LITIGATION			
9				
	This document relates to:			
10				
	All cases			
11				

12				
13	I, RONALD LINK, say that I have read the foregoing			
14	deposition and hereby declare under penalty of perjury the			
15	foregoing is true and correct:			
16	(as prepared) (as corrected on errata.)			
17	Executed this day of 20,			
18	at			
19				
20				
21				
22				
23	RONALD LINK			
24				

Case: 1:17-md-02804-DAP Doc#: 2173-39 Filed: 08/12/19 366 of 366 PageID #: 313689 Review

1		CORRECTION PAGE
2	DEPONENT:	RONALD LINK
3	DATE TAKEN:	DECEMBER 11, 2018
4	CASE:	NATIONAL PRESCRIPTION OPIATE LITIGATION
5	******	********
6	PAGE / LINE /	SHOULD READ/REASON
7	//	<i></i>
8	//	/
9	//	<i></i>
10	//	<i></i>
11	//	<u> </u>
12	//	/
13	//	<u> </u>
14	//	/
15	//	/
16	//	/
17	//	/
18	//	/
19	//	/
20	//	/
21	//	/
22	//	(
23	//	(
24	//	<i>(</i>